|
|
 Previous Article | Table of Contents | Next Article 
Therapy of patients with human T-cell lymphotrophic virus I-induced adult
T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for
interleukin-2
TA Waldmann, CK Goldman, KF Bongiovanni, SO Sharrow, MP Davey, KB Cease, SJ Greenberg and DL Longo
Metabolism Branch, National Cancer Institute, Bethesda, MD 20892.
Human T-cell lymphotropic virus I (HTLV-I)-induced adult T-cell leukemia
(ATL) cells constitutively express interleukin-2 (IL-2) receptors
identified by the anti-Tac monoclonal antibody (MoAb), whereas normal
resting cells do not. This observation provided the scientific basis for a
trial of intravenous anti-Tac in the treatment of nine patients with ATL.
The patients did not suffer untoward reactions and did not have a reduction
in the normal formed elements of the blood, and only one of the nine
produced antibodies to the anti-Tac MoAb. Three patients had transient
mixed, partial, or complete remissions lasting from 1 to more than 8 months
after anti-Tac therapy, as assessed by routine hematologic tests,
immunofluorescence analysis of circulating cells, and molecular genetic
analysis of HTLV-I provirus integration and of the T-cell receptor gene
rearrangement. The precise mechanism of the antitumor effects is unclear;
however, the use of a MoAb that prevents the interaction of IL-2 with its
receptor on ATL cells provides a rational approach for the treatment of
this malignancy.
Volume 72,
Issue 5,
pp. 1805-1816,
11/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G P Taylor
Molecular aspects of HTLV-I infection and adult T-cell leukaemia/lymphoma
J. Clin. Pathol.,
December 1, 2007;
60(12):
1392 - 1396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Brown, M. Bellon, and C. Nicot
Emodin and DHA potently increase arsenic trioxide interferon-{alpha}-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1
Blood,
February 15, 2007;
109(4):
1653 - 1659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. M. Foss, S. L. Aquino, and J. A. Ferry
Case 10-2003 - A 72-Year-Old Man with Rapidly Progressive Leukemia, Rash, and Multiorgan Failure
N. Engl. J. Med.,
March 27, 2003;
348(13):
1267 - 1275.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Phillips, B. Herring, L. A. Wilson, M. S. Rickford, M. Zhang, C. K. Goldman, J. Y. Tso, and T. A. Waldmann
IL-2R{{alpha}}-Directed Monoclonal Antibodies Provide Effective Therapy in a Murine Model of Adult T-Cell Leukemia by a Mechanism other than Blockade of IL-2/IL-2R{{alpha}} Interaction
Cancer Res.,
December 1, 2000;
60(24):
6977 - 6984.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. S. Gill, Y. C. Tsai, A. P. Rao, C. H. Spruck III, T. Zheng, W. A. Harrington Jr., T. Cheung, B. Nathwani, and P. A. Jones
Evidence for multiclonality in multicentric Kaposi's sarcoma
PNAS,
July 7, 1998;
95(14):
8257 - 8261.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Gill, W. Harrington, M. H. Kaplan, R. C. Ribeiro, J. M. Bennett, H. A. Liebman, M. Bernstein-Singer, B. M. Espina, L. Cabral, S. Allen, et al.
Treatment of Adult T-Cell Leukemia-Lymphoma with a Combination of Interferon Alfa and Zidovudine
N. Engl. J. Med.,
June 29, 1995;
332(26):
1744 - 1748.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Waldmann
Monoclonal antibodies in diagnosis and therapy
Science,
June 21, 1991;
252(5013):
1657 - 1662.
[Abstract]
[PDF]
|
|
|
|
|
